Drug
Notiretatug rezetecan clinical trials
Keep track of what changes. Save the notiretatug rezetecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 6 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 6
Shanghai Hengrui Pharmaceutical Co., Ltd. (8) · Fudan University (4) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3) · Henan Cancer Hospital (2) · Jiangsu HengRui Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Adebrelimab (6) · Trastuzumab rezetecan (3) · KRAS G12D Inhibitor HRS-4642 (2) · Tizetatug rezetecan (2) · Ruzaltatug rezetecan (2) · Famitinib (2) · Disitamab vedotin (2) · Choline (1)
Studies
Open first, then newest update. How each study uses notiretatug rezetecan is read from its arms, and is right about nine times in ten.
Testing it · 18
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingPhase 2Fudan UniversityNCT05076682Written as SHR-A2102
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as SHR-A2102
- A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06417554Written as SHR-A2102
- A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial CarcinomaRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07393542Written as SHR-A2102 and Adebrelimab
- A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07059221Written as SHR-A2102
- A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07418749Written as SHR-A2102 for Injection
- Exploratory Platform Research on Precision Therapy of Advanced Pancreatic CancerRecruitingPhase 2Fudan UniversityNCT06547736Written as SHR-A2102, HRS4642 and Adebrelimab
- Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer SubjectsRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07175220Written as SHR2554; SHR-A2102
- Phase I Study of SHR-A2102 in Patients With Advanced Solid TumorsRecruitingPhase 1Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05701709Written as SHR-A2102
- A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial CarcinomaRecruitingPhase 3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06738251Written as SHR-A2102 for Injection
- SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast CancerNot yet recruitingPhase 2Henan Cancer HospitalNCT06819319Written as SHR-A2102 ; Adebrelimab injection
- Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid TumorsNot yet recruitingPhase 1/2Henan Cancer HospitalNCT06955390Written as SHR-A2102+HRS-4642
- A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid TumorsRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06895928Written as SHR-A2102
- A Trial of SHR-A2102 for Treatment of Advanced Gynecological MalignancyRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06654440Written as SHR-A2102 for injection
- A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial CarcinomaRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06639347Written as SHR-A2102
- A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06589778Written as SHR-A2102
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as SHR-A2102
- A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.RecruitingPhase 1Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05735275Written as SHR-A2102
Given in every arm · 5 — notiretatug rezetecan is usual care beside what is tested
- Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerRecruitingPhase 2Beijing GoBroad HospitalNCT06433609Written as SHR-A2102
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLCNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07414953Written as SHR-A2102
- A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06512051Written as SHR-A2102 for Injection
- A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229729Written as SHR-A2102
- Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07041437Written as SHR-A2102
Codes
What other systems call notiretatug rezetecan · ClinicalTrials.gg INT016737
- UNII (FDA) H423BH2FBANOTIRETATUG REZETECANOne source FDA
- NCI Thesaurus C200198Notiretatug RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H423BH2FBA | NOTIRETATUG REZETECAN | One source FDA |
| NCI Thesaurus | C200198 | Notiretatug Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.